Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Vlado Perkovic's publication output changed over time?
ScholarIQpublication output · 2009–2022
Output grew0% over the shown period — from 1 works in 2009 to 1 in 2022.
1
1
2
1
2
1
1
2
1
200920102015201620172018201920212022
What are the most-cited papers on Vlado Perkovic?
ScholarIQmost cited works
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R. Matthews
New England Journal of Medicine. 20177,831 CitationsOPEN ACCESS
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg Jardine, Bruce Neal, Séverine Bompoint, Hiddo J.L. Heerspink, David M. Charytan, Robert Edwards, Rajiv Agarwal, George L. Bakris, Scott Bull, Christopher P. Cannon, George Capuano, Pei-Ling Chu, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol A. Pollock, David C. Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Gary Meininger, Barry M. Brenner, Kenneth W. Mahaffey
New England Journal of Medicine. 20196,091 CitationsOPEN ACCESS
Worldwide access to treatment for end-stage kidney disease: a systematic review
Thaminda Liyanage, Toshiharu Ninomiya, Vivekanand Jha, Bruce Neal, Halle Marie Patrice, Ikechi G. Okpechi, Ming‐Hui Zhao, Jicheng Lv, Amit X. Garg, John Knight, Anthony Rodgers, Martin Gallagher, Sradha Kotwal, Alan Cass, Vlado Perkovic
The Lancet. 20152,348 Citations
Chronic kidney disease
Kamyar Kalantar‐Zadeh, Tazeen H. Jafar, Dorothea Nitsch, Brendon L. Neuen, Vlado Perkovic
The Lancet. 20211,432 CitationsOPEN ACCESS
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E. Cooper, Steven E. Kahn, Nikolaus Marx, John H. Alexander, Michael Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, Hans J. Woerle, David Baanstra, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Jyothis T. George, Maximilian von Eynatten, Darren K. McGuire, for the CARMELINA Investigators
JAMA. 20181,089 CitationsOPEN ACCESS
Related on ScholarIQ
New South Wales Department of Health
Institution
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Paper
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Paper
Worldwide access to treatment for end-stage kidney disease: a systematic review
Paper
Chronic kidney disease
Paper
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Paper